Just saw something interesting and relevant while bouncing
Just saw something interesting and relevant while bouncing around the board for KMPH, which I own a little bit of. They have a PDUFA announcement slated for today so at some point it'll be approved or delayed. During late morning trading there was a stop loss raid that halted the market and got everyone hot and bothered about the potential for leaks about bad news. Someone posted a link to their slides from a past announcement to make others feel better and I found this little nugget that I think is relevant to where we sit with the FDA.
(I haven't tried to figure out the picture inlay thing so I'm just going to type out what was on their slide)
KP415 Updates
* Held KP415 NDA late-cycle review meeting with FDA on Dec 1, 2020
* FDA re-affirmed KP415 PDUFA date of Mar 2, 2021, no safety or efficacy issues were raised
* Next step is confidential review/negotiation of draft label
So you see, once a drug is about to gain approval there needs to be some confidential negotiations around labeling. I know that to be true in my heart but it's nice to see a company confirm that it goes down like that. Makes me feel even more confident about what's happening behind the scenes with CYDY.
Yours truly,
Daytime Respert
21
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...
Continue Reading
The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...
Continue Reading
The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...
Continue Reading
IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...
Continue Reading
Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...
Continue Reading
Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...
Continue Reading
A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...
Continue Reading
Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...
Continue Reading
Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...
Continue Reading
Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...
Continue Reading
Top 5 Most Recently Viewed Articles
Southwire's Bold Sustainability Vision for the Future Southwire's latest foray into sustainability leaves me chewing over a whole new set of ambitious targets. As the veteran player in North America's wire and cable scene, they're not just running the presses—they're mapping the future with grand gestures. July 30, 2026, marks their announcement of the 2025...
Continue Reading
Wells Fargo Announces Upcoming Earnings Report Wells Fargo & Company (NYSE: WFC) is set to reveal its fourth quarter earnings for 2024 on January 15. This anticipated announcement is scheduled to be shared around 7:00 a.m. Eastern time, allowing investors and financial enthusiasts to gain crucial insights into the company's financial performance and strategic direction....
Continue Reading
Breaking Down Schiff’s Take on Trade Look, this whole talk about foreign countries ripping off America? It’s a bunch of hot air, if you ask me. Peter Schiff, that famous economist who’s always got something to say, slammed that narrative recently. Ya know, he's making waves on X, saying, "No country has been ripping off America." I mean, he's basically flipping the...
Continue Reading
LifeMD Reports Impressive Financial Growth LifeMD, Inc. (NASDAQ: LFMD), a prominent virtual healthcare provider, has showcased remarkable resilience in its third-quarter financial results for the year. The company's total revenue has surged by 13% year-over-year, reaching $60.2 million, with adjusted EBITDA rising significantly by 20%, totaling $5.1 million. These results...
Continue Reading
Understanding the Class Action for Intellia Therapeutics As an investor in Intellia Therapeutics, Inc. (NASDAQ: NTLA), staying informed is vital, especially regarding your legal rights. Recently, the Rosen Law Firm, a notable player in the investor rights landscape, has issued reminders about a critical upcoming deadline concerning a class action lawsuit aimed at the...
Continue Reading